Regional disparities in cancer drug access have complex causes, including bureaucratic differences and variation in health care spending.
Case-control studies found no evidence of neurological or cardiac impairment in children exposed to chemotherapy or radiotherapy in utero.
While many facilities use some protective measures for chemo drugs, recent figures suggest that only 41% have adopted CSTDs.
With limited approval, a patchwork of state regulations regarding medical marijuana creates confusion among law enforcement and physicians alike.
Oncologists urged to speak out for increased regulation of laboratory-developed tests and uniformity among manufacturers in the U.S.
Using the right combination of drugs at a critical point in tumor evolution may stop the progression of heterogeneous tumors.
After approval and years of exposure in the general population, many medications have data analyses to identify unanticipated adverse events.
The right time for American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) on metastatic castration-resistant prostate cancer.
A recent study published in the Journal of Clinical Oncology links male pattern baldness with elevated risk of aggressive prostate cancer.
ALCHEMIST to screen 8,000 patients with early-stage lung cancer, randomly assigning patients with EGFR mutations or rearrangement of the ALK gene.
Newly released 2014 Cancer Progress Report from the American Association for Cancer Research highlights the need for increased federal funding of cancer research.
1 in 10 patients with cancer would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria.
A retrospective study identifies a potential link between NSAID use and breast cancer recurrence and overweight and obese women.
More research is warranted to determine the effectiveness of Botox® (onabotulinumtoxinA) injections in slowing the growth of tumors.
The new test is more sensitive than fecal occult blood tests but carries a higher risk of false-positives.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|